RU2009111605A - Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина - Google Patents
Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина Download PDFInfo
- Publication number
- RU2009111605A RU2009111605A RU2009111605/15A RU2009111605A RU2009111605A RU 2009111605 A RU2009111605 A RU 2009111605A RU 2009111605/15 A RU2009111605/15 A RU 2009111605/15A RU 2009111605 A RU2009111605 A RU 2009111605A RU 2009111605 A RU2009111605 A RU 2009111605A
- Authority
- RU
- Russia
- Prior art keywords
- radiation therapy
- agonist
- courses
- specified
- tumor
- Prior art date
Links
- 238000001959 radiotherapy Methods 0.000 title claims abstract 37
- 239000000556 agonist Substances 0.000 title claims abstract 29
- 206010070834 Sensitisation Diseases 0.000 title 1
- 230000008313 sensitization Effects 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract 18
- 108050009340 Endothelin Proteins 0.000 claims abstract 13
- 102000002045 Endothelin Human genes 0.000 claims abstract 13
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims abstract 13
- 108010091477 IRL 1620 Proteins 0.000 claims abstract 11
- DXPHNGAMYPPTBJ-TZMIJSMNSA-N irl 1620 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C(C)C)C1=CN=CN1 DXPHNGAMYPPTBJ-TZMIJSMNSA-N 0.000 claims abstract 11
- 239000000203 mixture Substances 0.000 claims abstract 11
- 230000001235 sensitizing effect Effects 0.000 claims abstract 8
- KIYSPBOGUDIMPC-SCGUGKIPSA-N 4-ala-endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)C1C=NC=N1 KIYSPBOGUDIMPC-SCGUGKIPSA-N 0.000 claims abstract 6
- 101710205037 Sarafotoxin Proteins 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 206010006187 Breast cancer Diseases 0.000 claims abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 4
- 206010025323 Lymphomas Diseases 0.000 claims abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 4
- 230000009885 systemic effect Effects 0.000 claims abstract 3
- 206010019695 Hepatic neoplasm Diseases 0.000 claims abstract 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 2
- 230000036770 blood supply Effects 0.000 claims abstract 2
- 201000009613 breast lymphoma Diseases 0.000 claims abstract 2
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 2
- 208000014018 liver neoplasm Diseases 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 201000001441 melanoma Diseases 0.000 claims abstract 2
- 206010027191 meningioma Diseases 0.000 claims abstract 2
- 230000001737 promoting effect Effects 0.000 claims abstract 2
- 208000023958 prostate neoplasm Diseases 0.000 claims abstract 2
- 238000007910 systemic administration Methods 0.000 claims abstract 2
- 238000011200 topical administration Methods 0.000 claims abstract 2
- 230000005855 radiation Effects 0.000 claims 4
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 3
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82419706P | 2006-08-31 | 2006-08-31 | |
| US60/824,197 | 2006-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009111605A true RU2009111605A (ru) | 2010-10-10 |
Family
ID=38920900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009111605/15A RU2009111605A (ru) | 2006-08-31 | 2007-08-27 | Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8394757B2 (enExample) |
| EP (1) | EP2059254B1 (enExample) |
| JP (1) | JP5306208B2 (enExample) |
| KR (1) | KR101547361B1 (enExample) |
| CN (1) | CN101534852B (enExample) |
| BR (1) | BRPI0722292A2 (enExample) |
| CA (1) | CA2661833C (enExample) |
| DK (1) | DK2059254T3 (enExample) |
| ES (1) | ES2541657T3 (enExample) |
| IL (1) | IL197335A (enExample) |
| MX (1) | MX2009002308A (enExample) |
| NO (1) | NO20091203L (enExample) |
| RU (1) | RU2009111605A (enExample) |
| WO (1) | WO2008027839A1 (enExample) |
| ZA (1) | ZA200901425B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| WO2008027839A1 (en) | 2006-08-31 | 2008-03-06 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| EP2187948A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of a peptide as a therapeutic agent |
| WO2010017332A2 (en) * | 2008-08-07 | 2010-02-11 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Radioprotectants targeting thrombospondin-1 and cd47 |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| US10323150B2 (en) | 2015-09-25 | 2019-06-18 | Nippon Kayaku Kabushiki Kaisha | Azo compound, ink composition, ink jet recording method, and colored article |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112954A (en) * | 1988-02-26 | 1992-05-12 | Neorx Corporation | Method of enhancing the effect of cytotoxic agents |
| US5550110A (en) | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| CA2135151A1 (en) | 1993-11-08 | 1995-05-09 | Mitsuhiro Wakimasu | Cyclic hexapeptides, their production and use |
| US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| AU686018B2 (en) | 1994-09-20 | 1998-01-29 | Amcor Packaging (New Zealand) Limited | A container |
| EP0799051B1 (en) | 1994-12-12 | 2005-07-27 | Omeros Corporation | Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound |
| EP0815870A3 (en) | 1996-06-27 | 2000-05-03 | Takeda Chemical Industries, Ltd. | Composition for prohylaxis or treatment of cerebral infarction |
| CA2268640A1 (en) | 1998-04-14 | 1999-10-14 | Mitsuru Shiraishi | Composition for preventing or treating ischemic disease |
| WO2000018393A1 (en) * | 1998-09-25 | 2000-04-06 | Warner-Lambert Company | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
| GB9910155D0 (en) | 1999-04-30 | 1999-06-30 | Microbiological Research Agenc | Augmented agglutination assay |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| EP1289558A2 (en) | 2000-05-31 | 2003-03-12 | Warner-Lambert Company Llc | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| WO2002049630A2 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030104976A1 (en) | 2001-07-23 | 2003-06-05 | Gudarz Davar | Analgesic methods using endothelin receptor ligands |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US20030229004A1 (en) * | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| US20040138121A1 (en) | 2002-10-24 | 2004-07-15 | Anil Gulati | Method and composition for preventing and treating solid tumors |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| US8217010B2 (en) | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| EP1819367B1 (en) * | 2004-11-22 | 2013-11-20 | The Board Of Trustees Of The University Of Illinois | Use of the endothelin etb receptor agonists irl-1620 in tumor imaging |
| CA2598439A1 (en) | 2005-02-22 | 2006-08-31 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| WO2008027839A1 (en) | 2006-08-31 | 2008-03-06 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
-
2007
- 2007-08-27 WO PCT/US2007/076903 patent/WO2008027839A1/en not_active Ceased
- 2007-08-27 US US11/845,648 patent/US8394757B2/en not_active Expired - Fee Related
- 2007-08-27 JP JP2009526850A patent/JP5306208B2/ja not_active Expired - Fee Related
- 2007-08-27 CN CN200780032550XA patent/CN101534852B/zh not_active Expired - Fee Related
- 2007-08-27 KR KR1020097006395A patent/KR101547361B1/ko not_active Expired - Fee Related
- 2007-08-27 MX MX2009002308A patent/MX2009002308A/es active IP Right Grant
- 2007-08-27 EP EP07841411.7A patent/EP2059254B1/en not_active Not-in-force
- 2007-08-27 DK DK07841411.7T patent/DK2059254T3/en active
- 2007-08-27 RU RU2009111605/15A patent/RU2009111605A/ru not_active Application Discontinuation
- 2007-08-27 ES ES07841411.7T patent/ES2541657T3/es active Active
- 2007-08-27 CA CA2661833A patent/CA2661833C/en active Active
- 2007-08-27 BR BRPI0722292-0A patent/BRPI0722292A2/pt not_active IP Right Cessation
-
2009
- 2009-02-27 ZA ZA200901425A patent/ZA200901425B/xx unknown
- 2009-03-01 IL IL197335A patent/IL197335A/en active IP Right Grant
- 2009-03-23 NO NO20091203A patent/NO20091203L/no not_active Application Discontinuation
-
2013
- 2013-02-06 US US13/761,043 patent/US8957014B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR101547361B1 (ko) | 2015-08-25 |
| ZA200901425B (en) | 2010-04-28 |
| CN101534852A (zh) | 2009-09-16 |
| CA2661833C (en) | 2016-01-26 |
| DK2059254T3 (en) | 2015-07-13 |
| US20080318846A1 (en) | 2008-12-25 |
| US8394757B2 (en) | 2013-03-12 |
| EP2059254A1 (en) | 2009-05-20 |
| JP2010502638A (ja) | 2010-01-28 |
| WO2008027839A1 (en) | 2008-03-06 |
| US20130150649A1 (en) | 2013-06-13 |
| ES2541657T3 (es) | 2015-07-23 |
| EP2059254B1 (en) | 2015-04-08 |
| KR20090069279A (ko) | 2009-06-30 |
| IL197335A (en) | 2013-07-31 |
| NO20091203L (no) | 2009-03-23 |
| CN101534852B (zh) | 2013-02-13 |
| JP5306208B2 (ja) | 2013-10-02 |
| CA2661833A1 (en) | 2008-03-06 |
| MX2009002308A (es) | 2009-09-07 |
| BRPI0722292A2 (pt) | 2014-04-15 |
| IL197335A0 (en) | 2011-08-01 |
| US8957014B2 (en) | 2015-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009111605A (ru) | Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина | |
| Kim et al. | Multifunctional trastuzumab–chlorin e6 conjugate for the treatment of HER2-positive human breast cancer | |
| PT910382E (pt) | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores | |
| Wu et al. | Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine | |
| Cui et al. | Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible | |
| Guo et al. | Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer | |
| JP2023024618A (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| Steinberg et al. | Intravesical and alternative bladder-preservation therapies in the management of non–muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin | |
| Qi et al. | Effects of palmatine hydrochloride mediated photodynamic therapy on oral squamous cell carcinoma | |
| JP2010502638A5 (enExample) | ||
| Hostetler et al. | Treatment of hematological malignancies with glycyrrhizic acid | |
| Qiu et al. | Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells | |
| ES2402232T3 (es) | Composiciones para contribuir al tratamiento del cáncer | |
| Josephson et al. | Superficial bladder cancer: part 2. Management. | |
| Kopp et al. | Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma | |
| Zygmunt et al. | Metabolism and structure of PDA as the target for new therapies: possibilities and limitations for nanotechnology | |
| Donson et al. | Tamoxifen radiosensitization in human glioblastoma cell lines | |
| Saif et al. | IPdR: a novel oral radiosensitizer | |
| Swami et al. | Eribulin in non-small cell lung cancer: challenges and potential strategies | |
| Saif | Targeting cancers in the gastrointestinal tract: role of capecitabine | |
| Ayash | High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer | |
| CN103961709A (zh) | 组蛋白甲基转移酶抑制剂与化疗剂组合在治疗肿瘤中的用途 | |
| Chen et al. | Ultrasound-responsive release of CD39 inhibitor overcomes adenosine-mediated immunosuppression in triple-negative breast cancer | |
| Komatsu et al. | Photosensitizer With Illumination Enhances In Vivo Antitumor Effect of Anti-ROBO1 Immunotoxin on Maxillary Sinus Squamous Cell Carcinoma | |
| Li et al. | Locally advanced pancreatic adenocarcinoma: Are we making progress? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20101220 |